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ABSTRACT
The major goal of radiotherapy is the induction of tumor cell death. Additionally, radiotherapy can
function as in situ cancer vaccination by exposing tumor antigens and providing adjuvants for anti-
tumor immune priming. In this regard, the mode of tumor cell death and the repertoire of released
damage-associated molecular patterns (DAMPs) are crucial. However, optimal dosing and fractionation
of radiotherapy remain controversial. Here, we examined the initial steps of anti-tumor immune priming
by different radiation regimens (20 Gy, 4 × 2 Gy, 2 Gy, 0 Gy) with cell lines of triple-negative breast
cancer in vitro and in vivo. Previously, we have shown that especially high single doses (20 Gy) induce a
delayed type of primary necrosis with characteristics of mitotic catastrophe and plasma membrane
disintegration. Now, we provide evidence that protein DAMPs released by these dying cells stimulate
sequential recruitment of neutrophils and monocytes in vivo. Key players in this regard appear to be
endothelial cells revealing a distinct state of activation upon exposure to supernatants of irradiated
tumor cells as characterized by high surface expression of adhesion molecules and production of a
discrete cytokine/chemokine pattern. Furthermore, irradiated tumor cell-derived protein DAMPs
enforced differentiation and maturation of dendritic cells as hallmarked by upregulation of co-stimula-
tory molecules and improved T cell-priming. Consistently, a recurring pattern was observed: The
strongest effects were detected with 20 Gy-irradiated cells. Obviously, the initial steps of radiotherapy-
induced anti-tumor immune priming are preferentially triggered by high single doses – at least in
models of triple-negative breast cancer.
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Introduction
The induction of tumor cell death and the abrogation of
clonogenic survival are considered the major determinants
in radio- and/or chemotherapy of cancer.1 However, mean-
while it is well accepted that immune mechanisms contribute
to the therapeutic outcome and that the mode of tumor cell
death determines if and to which extent irradiation converts
the tumor into an in situ vaccine.2–4 Apart from tumor anti-
gens which need to be made accessible to the immune system,
the presence of adjuvants orchestrating the recruitment, dif-
ferentiation, and activation of antigen-presenting cells (APCs)
in the tumor microenvironment is of pivotal importance for
the successful priming of anti-tumor immunity.5,6 In this
regard, tumor cells undergoing immunogenic forms of cell
death are known to release damage-associated molecular pat-
terns (DAMPs), including heat shock protein 70 (HSP70),
high mobility group box1 (HMGB1), and ATP, thereby sup-
porting the recruitment and maturation of APCs.7–10
However, the mode of cell death induced by ionizing irradia-
tion is not uniform, and it clearly depends on the irradiation
dose, the fractionation regimen, and the genetic repertoire of
the irradiated cells.3,10 Proliferating cells of the hematopoietic
system predominantly undergo apoptosis upon irradiation, as
characterized by externalization of phosphatidylserine, mem-
brane blebbing, chromatin condensation, and DNA fragmen-
tation, while the integrity of the plasma membrane remains
intact.11 If apoptotic cells are not removed in time by
CONTACT Kirsten Lauber kirsten.lauber@med.uni-muenchen.de Department of Radiation Oncology, University Hospital, Ludwig-Maximilians-Universität
München, Marchioninistrasse 15, 81377 Munich, Germany
*Both authors share equal first authorship
Color versions of one or more of the figures in the article can be found online at www.tandfonline.com/koni.
The supplementary data for this article can be accessed here.
ONCOIMMUNOLOGY
2019, VOL. 8, NO. 1, e1523097 (15 pages)
https://doi.org/10.1080/2162402X.2018.1523097
© 2019 The Author(s). Published with license by Taylor & Francis Group, LLC
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/),
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
professional or non-professional phagocytes, they progress
into secondary, post-apoptotic necrosis: The integrity of the
plasma membrane collapses, and intracellular contents,
including DAMPs, are released.3,12 In cells of epithelial origin,
the extent of apoptosis induction upon irradiation is rather
limited. As long as cell cycle checkpoint function is main-
tained, epithelial cells exit the cell cycle into cellular senes-
cence as hallmarked by upregulation of cyclin-dependent
kinase inhibitors, such as p16, p21, and p27, and expression
of senescence-associated β-galactosidase.13 If cell cycle check-
point function is impaired, persisting DNA damage will be
transferred into the next round of mitosis leading to aberrant
chromosomal segregation. Upon 2–3 rounds of anomalous
mitosis, highly aneuploid cells with huge and/or multiple
nuclei and abnormal morphology emerge. They may subse-
quently undergo a delayed form of apoptosis. More frequently
however, programmed necroptosis or uncontrolled necrosis
are observed, encompassing plasma membrane permeabiliza-
tion and/or rupture, cellular disintegration, and leakage of the
intracellular contents into the surroundings.10,14 In parallel to
the different modes of cell death, the induction of systemic
immune responses by local radiotherapy – known as radio-
therapy’s abscopal effects – varies widely with the model
systems and the radiation regimen employed.6,15–17
Investigations in different mouse tumor models revealed
that radiotherapy-induced anti-tumor immune reactions,
which are essentially dependent on type-I interferons (pro-
duced by the cyclic GMP-AMP synthase (cGAS)/stimulator of
interferon genes (STING) axis), APCs, and cytotoxic CD8+ T
cells, are exclusively stimulated by high single doses (10–
20 Gy).18–23 On the contrary, a recent study suggests that
3 × 8 Gy may be optimal.24 Clinically, abscopal tumor lesion
regression remains rare, most likely because comparable
super-hypofractionated protocols (fractions of >5 Gy) are
rarely used in the radiotherapeutic routine.
Systematic analyses addressing the immunological conse-
quences of different radiation regimens are scarce. Therefore,
the present study was designed to examine the initial steps of
anti-tumor immune priming by radiotherapy with specific
focus on endothelial cell activation, recruitment and activa-
tion of APCs in the context of different radiation regimens.
We chose cell lines of triple-negative breast cancer (histologi-
cally negative for estrogen, progesterone, and Her2/neu recep-
tors) as our model systems, since this breast cancer subtype is
associated with particularly poor prognosis. No targeted ther-
apy is currently available, and due to early and extensive
metastasis formation, patients with this subtype may have
relevant benefits from radiotherapy-induced anti-tumor
immune responses.25 Interestingly, a recent study provided
evidence that the expression levels of pro-necrotic signaling
genes correlate with the ones of intra-tumoral immune cell
subsets suggesting that necrotic processes may be involved in
controlling intra-tumoral immune responses in human breast
cancer.26
Previously, we have shown that particularly high single
dose irradiation at 20 Gy stimulates a late-onset type of
primary necrosis in triple-negative breast cancer cells reveal-
ing a chaotic morphology with features of mitotic catastrophe
and plasma membrane disintegration.11,27 Here, culture
supernatants of these dying cells were analyzed for their
effects on endothelial cell activation as well as the recruitment
and activation of APCs in vitro and in vivo. The results were
compared to supernatants of 4 × 2 Gy-, 2 Gy-, and sham-
irradiated cells. Our data show that high single dose irradia-
tion leads to the release of protein DAMPs which trigger a
distinct state of activation in endothelial cells as characterized
by upregulation of adhesion molecules, and a cytokine/che-
mokine expression pattern dominated by IL-6, CXCL1, −2,
−3, and CCL7, leading to sequential recruitment of neutro-
phils and monocytic cells in vivo. In vitro, the presence of
these tumor cell-derived DAMPs enforced differentiation and
maturation of human monocyte-derived dendritic cells (DCs),
resulting in improved T cell activation.
Results
Irradiated tumor cell-derived DAMPs stimulate
recruitment of neutrophils and monocytic cells in vivo
Previously, we have shown that γ-irradiation induces different
forms of cell death in breast cancer cells depending on the
radiation regimen and the genetic composition of the irra-
diated cells.27 In triple-negative breast cancer cells, such as
HCC1937 cells, we observed a delayed type of primary necro-
sis with chaotic morphology which was particularly promi-
nent 4 days after irradiation with a high single dose of 20 Gy
(Supplemental Figure 1,27).
In the present study, we examined the recruitment of
myeloid cells by culture supernatants of irradiated tumor
cells in vivo. We utilized an air pouch model, where
supernatants of HCC1937 cells (harvested 4 days after
irradiation at 0 Gy, 2 Gy, daily 2 Gy, and 20 Gy) were
injected, and the dynamics of myeloid cell subset recruit-
ment were analyzed in the air pouch lumen as well as in
the air pouch skin (Figure 1(a)). Unconditioned culture
medium served as negative control, and tumor necrosis
factor (TNF) was used as positive control (Figure 1(b)).
Hematoxylin/eosin (H&E) staining reproducibly demon-
strated a well-defined structure of the air pouch skin
(Figure 1(c)): Distant from the lumen, muscle and fat
cells with small inner vessels were overlain by loose con-
nective tissue covered by several cell layers with squamous
epithelial morphology proximal to the pouch lumen.
Polymorphonuclear neutrophils (PMNs) were observed to
different extents inside the muscle, the connective tissue,
and the squamous epithelial layer indicating active infil-
tration of PMNs from the small vessels into the pouch
cavity. This was most obvious in pouches that had been
treated with TNF, 4 × 2 Gy, and 20 Gy culture
supernatants.
In order to dissect myeloid subsets and the time course
of their infiltration, skin samples were subjected to con-
focal immunofluorescence microscopy (Figure 1(d)).
Ly6G+ neutrophils swiftly accumulated up to 6 h after
injection. After 12 h, these neutrophils had gradually dis-
appeared, and F4/80+ monocytic/macrophagocytic cells
were observed. The numbers of F4/80+ cells further
increased up to 24 h after supernatant injection.
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Importantly, there were clear differences between the
radiation regimens. The strongest effects were seen with
supernatants of 20 Gy-irradiated cells.
Via flow cytometric analyses of the air pouch lavages
we further characterized the recruited myeloid cells and
quantified the dynamics of the infiltration process
(Figure 2(a)). The number of recruited CD45+ cells
increased over time with a maximum 6 h after injection,
followed by a decrease down to baseline levels. This was
dominated by Ly6G+ neutrophils and was strongest when
supernatants of 20 Gy-irradiated cells were injected.
Supernatants of 4 × 2 Gy- and 2 Gy-irradiated cells
recruited lower levels of CD45+ cells, while CD45+ cells
barely exceeded control levels when supernatants of non-
irradiated cells were deployed. Apart from neutrophils,
Ly6Chi and Ly6Clo monocytes were observed, yet in
lower numbers. The infiltration kinetics of Ly6Chi and
Ly6Clo monocytes were delayed as compared to those of
Ly6G+ neutrophils, and the maximal monocyte numbers
were detected 12 h after supernatant injection. Again,
highest cell numbers were found with supernatants of
20 Gy-irradiated cells. Virtually the same observations
were made when supernatants of irradiated HCC1806
cells were employed in the air pouch model. Yet, here
the difference between irradiation at 20 Gy and all other
irradiation regimens was even more pronounced
(Supplemental Figure 3).
Quantitative realtime PCR (qRT-PCR)-analyses of the
air pouch skin samples confirmed the recruitment of mye-
loid cells stimulated by dying tumor cell-derived super-
natants (Figure 2(b)). The kinetics of L-selectin mRNA
levels, a leukocyte marker, paralleled the infiltration pat-
tern as detected by flow cytometry and confocal micro-
scopy. This was preceded by an early increase in mRNA
expression of IL-6 and IL-1β and chemokines including
CXCL1, −2, and −3. Obviously, cells in the air pouch skin
Figure 1. In vivo recruitment of myeloid cell subsets stimulated by supernatants of irradiated tumor cells in an air pouch model. (a) Schematic representation of the
treatment sequence in air pouch experiments. (b) Representative photographs of native air pouch skin samples (luminal side) 12 h after injection of control medium
or medium supplemented with 50 ng/ml TNF. (c) Paraffin sections (3 µm) of representative air pouch skin samples 12 h after injection of the indicated supernatants
of irradiated HCC1937 cells or respective control stimuli (medium or 50 ng/ml TNF) were subjected to H&E-staining. 20x magnification, scale bar 50 µm. Arrowheads
indicate PMNs in the TNF sample. (d) Exemplary air pouch skin samples were prepared, stained, and examined by confocal immunofluorescence microscopy. For the
visualization of endothelial cells, neutrophils, and macrophages, immunostaining against PECAM-1 (blue), Ly6G (red), and F4/80 (green) was performed. 20x
magnification, scale bar 100 µm.
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were stimulated to produce these mediators upon expo-
sure to dying tumor cell-derived supernatants and thus are
likely to orchestrate the directional recruitment of myeloid
cells in vivo.
Endothelial cells are activated by protein DAMPs from
irradiated tumor cells via contribution of toll-like
receptor 4
Recruitment of leukocytes to sites of tissue damage and/or
infection is highly dependent on the activation of endothelial
cells. Activated endothelial cells express adhesion molecules
and release and/or deposit chemokines on their surface in
order to attract leukocytes and facilitate their extravasation.28
Based on our observations in the air pouch model, the influ-
ence of irradiated tumor cells on endothelial cell activation
was examined. To this end, human umbilical vein endothelial
cells (HUVECs) were treated with supernatants of irradiated
tumor cells, and surface expression of the adhesion molecules
ICAM-1, VCAM-1, and E-selectin was visualized by immuno-
fluorescence on native, non-fixed cells (Figure 3(a)). Clear
differences between the radiation regimens were observed:
Whereas no expression of adhesion molecules was detected
on HUVECs exposed to supernatants of sham-irradiated cells,
supernatants of 2 Gy- and 4 × 2 Gy-irradiated cells induced a
moderate increase, and exposure to supernatants of 20 Gy-
irradiated cells resulted in a strong upregulation. These obser-
vations were confirmed with supernatants of other breast
cancer cell lines showing similar patterns of cell death induc-
tion upon irradiation (Supplemental Figure 4,27). The extent
of ICAM-1 and E-selectin surface upregulation was quantified
by fluorometric analyses and did further strengthen our
microscopy findings with the most prominent effects being
observed upon exposure to supernatants of 20 Gy-irradiated
cells (Figure 3(b) and Supplemental Figure 5(a)). Biochemical
characterization revealed that the molecular entities responsi-
ble for stimulation of adhesion molecule upregulation are
protein DAMPs as they were sensitive to proteinase K diges-
tion and exhibited an apparent molecular weight of >10 kDa
(Figure 3(c) and Supplemental Figure 5(b)). Potential candi-
dates for these protein DAMPs are HSP70, HMGB1, and
S100A8/A9 dimer, since all of them were time- and dose-
dependently released by irradiated tumor cells as detected by
ELISA measurements (Figure 3(d)). While the lowest concen-
trations were found in the non-irradiated controls, irradiation
at 2 Gy and 4 × 2 Gy resulted in a clear increase in DAMP
concentration. Importantly, highest concentrations were mea-
sured after irradiation at 20 Gy, thus matching the pattern of
endothelial cell activation. Protein DAMP release was con-
firmed in supernatants of other irradiated triple-negative
breast cancer cell lines (Supplemental Figure 6).
Next, we focused on the corresponding receptors which
mediate HUVEC activation. As such, toll-like receptor 4
(TLR4) and/or the TLR2/TLR4 heterodimer represent com-
mon receptors for HMGB1, HSP70, and S100A8/A9.29–31
Importantly, when TLR4 was blocked using the antagonist
RS-LPS, HUVEC activation as measured by upregulation of
ICAM-1 surface expression was strongly, yet not completely
inhibited (Supplemental Figure 7A). Reporter cell lines con-
firmed the activation of TLR4 and TLR2 by supernatants of
Figure 2. Dynamics of leukocyte recruitment and mRNA expression of crucial regulator molecules in the air pouch microenvironment. (a) Dynamics of leukocyte
recruitment into the air pouch lumen. Air pouch lavages were collected at the indicated time points, and leukocyte subsets were analyzed by flow cytometry. Total
cell numbers per pouch are shown (n = 6 animals for supernatants, n = 2 animals for the control stimuli medium or 50 ng/ml TNF). Means ± SEM are depicted, and
p-values were calculated by two-way ANOVA with Bonferroni-Holm correction. (b) mRNA expression of key regulator molecules in the air pouch microenvironment.
Air pouch skin samples (n = 6 animals for cell culture supernatants, n = 2 animals for the control stimuli medium or 50 ng/ml TNF) were subjected to realtime qRT-
PCR. Results were normalized on a reference gene matrix of 18S rRNA, δ-ALAS, β-actin, α-tubulin, and PECAM-1, and calibrated on the medium-injected controls.
Means of log2 expression values are depicted.
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irradiated breast cancer cells (Supplemental Figure 7B, C).
Hence, TLR4 and/or the TLR2/4 heterodimer are activated
by protein DAMPs released from irradiated breast cancer cells
and appear to be involved in the regulation of endothelial cell
activation. Nevertheless, further receptors, including RAGE
and members of the scavenger receptor family, which also
have been reported as receptors for dying cell-derived protein
DAMPs, may additionally contribute.32
Upregulation of adhesion molecule expression in
HUVECs was also detected on the mRNA level as con-
firmed by qRT-PCR analyses (Figure 4(a)). This was
accompanied by upregulation of diverse chemokines and
cytokines involved in the recruitment process whose
expression thus constitutes another hallmark of endothelial
cell activation. Intriguingly, although there were several
similarities, the activation pattern of endothelial cells
exposed to supernatants of irradiated cells was clearly dis-
tinct from the one stimulated by TNF. Dimensionality
reduction by principal component analysis revealed three
activation states, (i) the TNF-positive control samples, (ii)
the 20 Gy-irradiated samples, and (iii) the remaining sam-
ples, including the other radiation regimens and the med-
ium control (Figure 4(b)). The biplot diagram clearly shows
that IL-6, CXCL1, −2, and to a lesser extent also CXCL3
and CCL7 represent the variables with the highest loadings
for PC2 which predominantly separates the 20 Gy samples
from all others. Accordingly, they appear to be the major
determinants of the HUVEC response towards supernatants
of irradiated tumor cells. Multiplex-ELISA measurements
confirmed the increased production of these cytokines and
chemokines on the secretome level (Figure 4(c)). Elevated
concentrations of IL-6, CXCL1, CXCL2, and CCL7 were
secreted by HUVECs after incubation with conditioned
media of irradiated tumor cells in comparison to sham-
irradiated controls or unconditioned medium, respectively.
The same trend was observed for CXCL8, CCL2, and IL-1β.
Figure 3. In vitro endothelial cell activation and upregulation of adhesion molecule surface expression are mediated by protein DAMPs derived from irradiated tumor
cells. (a) Representative photographs of immunofluorescent adhesion molecule surface staining on HUVECs 4 h after exposure to supernatants of irradiated HCC1937
cells. Surface expression was visualized by immunofluorescence microscopy on native, non-fixed HUVECs. Medium and TNF (50 ng/ml) served as controls. 63x
magnification, scale bar 50 µm. (b) Quantitation of ICAM-1 surface expression on HUVECs by fluorometric measurement. HUVECs were treated as in (a) and subjected
to native immunofluorescence staining. Staining intensities were quantified by fluorometric measurement, and x-fold expression levels were calculated as the means
of fluorescence intensities subtracted by the corresponding isotype controls and normalized to the 0 Gy samples (n = 9 independent experiments). p-values were
calculated by unpaired Student’s t-tests with Bonferroni-Holm correction. (c) Biochemical characterization of the molecular entities mediating upregulation of ICAM-1
expression. Supernatants of 20 Gy-irradiated HCC1937 cells were applied to membrane centrifugation (molecular weight cut-off 10 kDa) or proteinase K treatment
prior to incubation with HUVECs. ICAM-1 surface expression was measured as in (b) (n = 5–10 independent experiments). Group comparison was performed by
unpaired Student’s t-test with Bonferroni-Holm correction. (d) HSP70, HMGB1, and S100A8/A9 were quantified in supernatants of irradiated HCC1937 cells by ELISA.
Concentrations were calculated on the basis of standard curves. Means ± SD of 3 (HSP70), 4 (HMGB1), or 5 (S100A8/A9) independent experiments are shown. Group
comparison was carried out by two-way ANOVA with Bonferroni-Holm correction.
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Protein levels of secreted cytokines and chemokines showed
analogous patterns as the mRNA levels. The strongest
increase was detected in response to supernatants of
20 Gy-irradiated cells, and weaker effects were seen with
supernatants of 4 × 2 Gy- and 2 Gy-irradiated cells.
Functionally, HUVEC activation was paralleled by
improved adhering and crawling of PMNs in in vitro flow
chamber experiments (Supplemental Figure 8). Yet, this did
not reach statistical significance.
Protein DAMPs from irradiated tumor cells enforce
differentiation and maturation of APCs
In the air pouch experiments, we did not detect relevant
recruitment of APCs, such as DCs (Figure 2(a) and
Supplemental Figure 3). Nevertheless, Ly6Chi monocytic
cells have the potential to differentiate into several subsets
with antigen-presenting and cross-presenting capacity.33 This
requires upregulation of peptide-presenting MHC class II and
class I molecules as well as enhanced expression of co-stimu-
latory signals, including CD80, CD86, and CD40, which are
necessary for proper T cell activation via CD28 and CD40L.34
Along these lines, it becomes increasingly evident that mono-
cytic cells can give rise to a population of monocytic APCs
which are of importance for the stimulation of anti-tumor
immune mechanisms during cancer therapy – at least in
mouse tumor models.8,35,36 For anthracycline-based che-
motherapy, it has already been shown that dying cancer cells
can stimulate the differentiation of recruited monocytes into
antigen-presenting DCs.8 Thus, we hypothesized that similar
effects on DC differentiation and maturation may be induced
by irradiated, dying cancer cells.
In the differentiation approach, primary human monocytes
were stimulated with supernatants of irradiated tumor cells
Figure 4. Upregulation of cytokines and chemokines in endothelial cells upon exposure to supernatants of irradiated tumor cells. (a) mRNA expression levels of
crucial adhesion molecules, cytokines, and chemokines. HUVECs were incubated with supernatants of irradiated HCC1937 cells for 4 h as in Figure 3. mRNA
expression levels were determined by qRT-PCR, normalized on a reference gene matrix of 18S rRNA, β2-microglobulin, and δ-ALAS, and calibrated on the respective
medium-treated samples. TNF (50 ng/ml) served as positive control. Unsupervised hierarchical clustering of log2 expression values of 4 independent experiments is
depicted (na indicates not assessed). (b) Principal component analysis (PCA) of mRNA expression data from (a). The biplot shows the scores of the samples (black
coordinate system) and the scaled loadings of the input variables (green coordinate system) in the subspace of the first two principal components. (c) Cytokines and
chemokines released from HUVECs were measured by multiplex-ELISAs after exposure to supernatants of irradiated HCC1937 cells for 4 h and incubation in fresh
medium for two more hours. Concentrations were calculated on the basis of standard curves. n = 3 independent experiments are shown (nd indicates not
detectable), and p-values were determined by unpaired Student’s t-tests with Bonferroni-Holm correction.
e1523097-6 J. KROMBACH ET AL.
followed by in vitro differentiation into DCs with IL-4 and
GM-CSF for 5 days. Characteristic DC markers of the immu-
nological synapse were monitored by flow cytometry. The co-
stimulatory ligands CD80 and CD86, the DC maturation
marker CD83, the co-activating receptor CD40, and the
MHC class II molecule HLA-DR were increased after mono-
cyte exposure to supernatants of irradiated tumor cells
(Figure 5(a)). The most prominent effects were observed in
case of CD80 surface expression. Supernatants of 20 Gy-irra-
diated cells stimulated the strongest increase, while this was
reduced with supernatants of 4 × 2 Gy- and 2 Gy-irradiated
cells. Biochemical characterization of the responsible DAMPs
was performed analogously to the experiments on endothelial
cell activation (Figure 3(c)). Proteins >10 kDa were again
identified as the relevant mediators (Figure 5(b)).
Next, the influence of irradiated tumor cell-derived
DAMPs on DC maturation was examined. To this end, DCs
differentiated for 5 days from primary human monocytes
were exposed to supernatants of irradiated tumor cells for
2 days. The changes in the expression pattern of DC markers
were similar to the ones observed in the differentiation
approach (Figure 5(c)). Again, the strongest upregulation
was detected in case of CD80. Supernatants of 20 Gy-irra-
diated cells induced the highest increase in CD80 expression,
and protein DAMPs >10 kDa were responsible for the upre-
gulation (Figure 5(d)).
Effector functions of APCs are improved after exposure to
irradiated tumor cells
Upon recruitment and differentiation of APCs, uptake of
antigen material is the next step in generating an anti-tumor
immune response.5 We examined tumor antigen uptake by
co-incubating DCs with tumor cells in increasing target:effec-
tor ratios. Phagocytosis was analyzed by flow cytometry and
live cell imaging (Figure 6(a) and Supplemental Movies). As
expected, the percentage of phagocytosing DCs increased with
rising target:effector ratios, and irradiated prey cells were
significantly better engulfed than non-irradiated controls.
Addition of the actin polymerization inhibitor cytochalasin
D prior to the phagocytosis assay confirmed active internali-
zation (Figure 6(b)).
Finally, we investigated the activation of T cells by APCs
upon exposure to irradiated tumor cell supernatants. Mixed
leukocyte reactions of DCs with allogeneic T cells were set up,
and proliferation of CFSE-labeled CD4+ and CD8+ T cells was
measured by flow cytometry (Figure 6(c)). Whereas CD4+ T
cell proliferation was only slightly affected, proliferation of
CD8+ T cells was significantly increased when DCs had been
differentiated in the presence of supernatants of 20 Gy-irra-
diated tumor cells.
Discussion
Radiotherapy is a cornerstone of cancer treatment and can
significantly prolong overall survival – not only in breast
cancer.37 In addition to its direct tumoricidal effects, radio-
therapy is known to induce distinct changes in the tumor
microenvironment, particularly in the leukocyte
compartment.38 Meanwhile, it is well acknowledged that
anti-tumor immune mechanisms can be stimulated by radio-
therapy in the sense of an in situ cancer vaccination.4,6
However, the optimal dosing and fractionation regimen for
the induction of anti-tumor immunity by ionizing irradiation
remain controversial.21,39–41
In the present study, we systematically analyzed the initial
steps of anti-tumor immune priming by radiotherapy in com-
plementary in vivo and in vitro models. We focused on triple-
negative breast cancer cells and examined the effects of dying
tumor cell-derived DAMPs on endothelial cell activation, as
well as on the recruitment and differentiation of APCs in the
context of different irradiation doses and fractionation
regimens.
The activation of endothelial cells is a prerequisite for
immune cell trafficking.28 Endothelial cells upregulate adhe-
sion molecules such as E-selectin, ICAM-1, and VCAM-1,
and release and/or deposit chemokines on their cell surface
in order to facilitate the extravasation of leukocytes from the
bloodstream into the tissue.28 We observed a strong upregula-
tion of E-selectin, ICAM-1, and VCAM-1 on endothelial cells
mediated by protein DAMPs derived from irradiated tumor
cells that was part of a distinct activation pattern – clearly
different from the one stimulated by TNF and characterized
by induction and release of IL-6, CXCL1, CXCL2, and CCL7.
This was most pronounced upon exposure to supernatants of
20 Gy-irradiated tumor cells which at the time point of super-
natant collection had undergone a late-onset type of primary
necrosis.27 Similar patterns of endothelial cell and/or pericyte
activation have been reported in the field of sterile inflamma-
tion with models of laser injury and hot needle injury.42–44
Obviously, the forms of necrotic cell death which are induced
by single high dose irradiation, laser injury and hot needle
injury as well as the repertoire of released DAMPs share
similarities, irrespective if the dying cells are malignant or
not. This is further underlined by the dynamics of myeloid
cell recruitment: Initially, neutrophils are recruited followed
by monocytic cells in a second wave.45 This seems to be
different from intra-tumoral leukocyte recruitment described
in the context of anthracycline-based chemotherapy. Here, the
crucial mediators have been identified as dying tumor cell-
derived ATP, CCL2, and −7, and the authors have not
described an initial neutrophil phase.8,35 Although nucleo-
tides, including ATP, are released from irradiated tumor
cells and stimulate chemokinetic monocyte migration in
vitro, data from this and our previous study suggest that
they fail to induce directional monocyte migration and do
not contribute to endothelial cell activation.27 Nevertheless,
they may act as local amplifiers of recruitment signals. 46,47
Neutrophil recruitment by dying tumor cells has been
described recently in a mouse model where culture super-
natants of tunicamycin- or mitoxanthrone-treated tumor
cells were injected into the ear pinnae and in different
mouse flank tumors irradiated with high single doses of
15 Gy,48,49 thus confirming our air pouch findings. The
authors of both studies also observed an essential contribution
of CXCL1 together with CCL2, CXCL10, and G-CSF. The role
of neutrophils recruited by dying tumor cells during radio-
and/or chemotherapy still remains to be defined. Yet,
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Figure 5. Differentiation andmaturation of antigen presenting cells is stimulated by proteinDAMPs released from irradiated tumor cells. (a) Differentiation ofmonocyte-derived
DCs. Primary humanmonocytes were stimulated for 4 h with supernatants of irradiated HCC1937 cells followed by differentiation into DCs with 40 ng/ml IL-4 and 20 ng/ml GM-
CSF for 5 days. Surfacemarker expressionwasmeasuredby flow cytometry. LPS (200 ng/ml) served as positive control. x-fold increase in surfacemarker expressionwas calculated
from isotype-subtracted median fluorescence intensities normalized on the corresponding 0 Gy samples. Results from 5 independent experiments are shown, and group
comparison was performed by two-sided exact Wilcoxon rank test with Bonferroni-Holm correction. (b) Biochemical characterization of the responsible molecular entities.
Supernatants of 20Gy-irradiatedHCC1937 cells were subjected tomembrane centrifugation (molecular weight cut-off 10 kDa) and proteinase K digestion prior to incubationwith
monocytes. CD80 surface expression was determined as in (a). Data from 5–10 independent experiments are shown, and group comparison was performed by two-sided exact
Wilcoxon rank test with Bonferroni-Holm correction. (c) Maturation of immature DCs. Immature DCswere differentiated fromprimary humanmonocytes with IL-4 (40 ng/ml) and
GM-CSF (20 ng/ml) for 5 days. DCs were then stimulated with supernatants of irradiated HCC1937 cells for 2 days and examined by flow cytometry. TNF (100 ng/ml) served as
positive control. Data from 5 independent experiments are presented, and p-values were calculated by two-sided exact Wilcoxon rank test with Bonferroni-Holm correction. (d)
Biochemical characterization. Prior to incubation with DCs, supernatants of 20 Gy-irradiated HCC1937 cells were applied to membrane centrifugation or proteinase K digestion,
respectively, as in (b). Data from 5–10 independent experiments are shown, and group comparison was performed by two-sided exact Wilcoxon rank test with Bonferroni-Holm
correction.
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evidence is available that neutrophils can engulf dying tumor
cells, exert cytotoxic activity against residual, therapy-surviv-
ing tumor cells, and thus can contribute to therapy-induced
tumor control.48,49 Additionally, neutrophils are able to create
a favorable chemokine milieu for the invasion of monocytic
cells and tumor-specific cytotoxic T cells.45,49
The role of intra-tumorally recruited monocytic cells in
therapeutic settings clearly is subtype-dependent.
Anthracycline-based chemotherapy stimulates intra-tumoral
infiltration of Ly6Chi monocytic cells which further differ-
entiate into APCs.8,35 Additionally, Ly6Chi monocytes per se
appear to be able to efferocytose dying tumor cells and
cross-present tumor antigens to CD8+ T cells.50 However,
tumor-promoting monocytic myeloid-derived suppressor
cells (MDSCs) also share certain phenotypic similarities
with inflammatory Ly6Chi monocytes.51 A recent study
provided evidence that antigen-presenting Ly6ChiCD103+
monocytic cells which accumulate intra-tumorally during
immunogenic chemotherapy and exert crucial functions as
“first responders” in initiating an anti-tumor response can
emerge from tumor-resident MDSC as well as from bone-
marrow-derived monocytic precursors.36 Thus, it will be
interesting to dissect the differentiation fate and function-
ality of the Ly6Chi monocytes that were recruited by super-
natants of irradiated tumor cells in our model in greater
detail, for instance if they – in the course of differentiation
– give rise to the Ly6Clo monocytic population which
appeared in the air pouches, or if these cells rather are of
tissue-resident origin.52
In terms of differentiation and functionality, newly
recruited monocytic cells of CD11c+CD11b+Ly6Chi pheno-
type have been shown to upregulate co-stimulatory marker
expression and appear to be potent inducers of anti-tumor
immunity.8,36 This is in accordance with our in vitro
observations with human monocytes whose differentiation
into DCs, maturation, and predominantly the upregulation
of CD80 and CD86 was enhanced in the presence of
supernatants of irradiated tumor cells. Functionally, this
was paralleled by improved stimulation of allogeneic
CD8+, and to a lesser extent also CD4+ T cells with the
strongest effects seen with supernatants of 20 Gy-irra-
diated tumor cells. These observations are in line with
previous reports showing that local and systemic anti-
tumor immunity induced by radiotherapy relies on CD8+
T cells.21,53
Throughout our study, we observed protein DAMPs
with an apparent molecular weight >10 kDa to be respon-
sible for endothelial cell activation, as well as differentia-
tion and maturation of APCs, whereas the migratory
activity of monocytic cells in our previous study was
mainly controlled by apyrase-sensitive, low-molecular
weight nucleotides.27 Obviously, different classes of
DAMPs exert complementary functions, and the details
of their contribution require further investigation. Within
the class of protein DAMPs, we could detect high levels
of HMGB1, HSP70, and S100A8/A9 in the supernatants
of irradiated tumor cells. All of them are known to be
potent mediators of endothelial cell activation as well as
recruitment and differentiation of APCs,54–56 and they
exert their functions via common receptors, including
TLR4, the TLR2/4 dimer, RAGE, and members of the
scavenger receptor family.57–59 Accordingly, protein
DAMP-stimulated TLR4-signaling has been reported to
be essential for anti-tumor immune priming in the con-
text of radiation and chemotherapy.60,61 Our results on
TLR4 activation and its involvement in endothelial cell
activation confirm these reports. However, if and to
which extent this receptor-ligand axis may be accessible
for targeted therapeutic intervention in combined modal-
ity approaches of radiotherapy needs to be clarified.
Figure 6. Effector functions of antigen presenting cells are enhanced upon contact with irradiated tumor cells. (a) Phagocytosis and antigen uptake. Immature DCs
were differentiated from primary human monocytes (PKH67-labeled) with 40 ng/mL IL-4 and 20 ng/mL GM-CSF for 5 days. Afterwards, DCs were co-incubated with
irradiated HCC1937 cells (4 days after irradiation, PKH26-labeled) at the indicated target:effector ratios. Phagocytosis was allowed for 2 h and analyzed by flow
cytometry. The percentage of double-positive DCs with ingested HCC1937 cell material is shown as means ± SD of 5 independent experiments. Group comparison
was calculated by two-way ANOVA with Bonferroni-Holm correction. (b) DCs were incubated with 20 µM cytochalasin D 1 h prior to performing the phagocytosis
assay at a ratio of 1:4 as in (a). (c) Priming of T cell proliferation. DCs were differentiated from primary human monocytes upon exposure to supernatants of irradiated
HCC1937 cells or TNF (100 ng/ml) as in Figure 5A. After 7 days, DCs were co-incubated with CFSE-labeled T cells from an allogeneic donor at a ratio of 1:5 (DC:T cells)
for additional 5 days before T cell proliferation was analyzed by flow cytometry. The percentage of proliferating T cells was calculated as the percentage of
CD3+CFSElowCD4+ or CD3+CFSElowCD8+ on the basis of all CD3+CD4+ or CD3+CD8+ cells, respectively. Results were normalized on the corresponding 0 Gy samples
and are displayed as data from 6 independent experiments. Group comparison was carried out by two-sided exact Wilcoxon rank test with Bonferroni-Holm
correction.
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Overall, our study elucidates the early steps of anti-tumor
immune priming in the context of cancer radiotherapy and
identifies dying cell-derived protein DAMPs, which are most
strongly released upon irradiation at high single doses by
tumor cells undergoing a delayed type of primary necrosis,
as crucial regulators of endothelial cell activation as well as
recruitment and differentiation of APCs.
Materials and methods
Primary cells, cell lines, and cell culture supernatants
HCC1937 and HCC1806 cells were obtained from ATCC
(Manassas, VA, USA) and cultured in RPMI-1640 medium
supplemented with 10% fetal calf serum (FCS), 100 units/
ml penicillin, 0.1 mg/ml streptomycin, and 10 mM HEPES
(all from Thermo Scientific, Schwerte, Germany) in water-
saturated atmosphere at 37°C and 5% CO2. MDA-MB-436
cells were purchased from CLS (Heidelberg, Germany) and
cultured in DMEM/F12 medium supplemented with 10%
FCS, 100 units/ml penicillin, and 0.1 mg/ml streptomycin.
HEK-BlueTM hTLR2 and HEK-BlueTM hTLR4 reporter cell
lines were obtained from InvivoGen (Toulouse, France) and
maintained in DMEM medium supplemented with 10%
FCS, 50 units/ml penicillin, 0.05 mg/ml streptomycin,
100 µg/ml NormocinTM (InvivoGen), and selection antibio-
tics. Cell line authentication was performed by short tan-
dem repeat (STR) typing (service provided by the DSMZ,
Braunschweig, Germany), and cells were routinely screened
to be free from mycoplasma contamination (MycoAlertTM
Lonza, Basel, Switzerland). HUVECs were obtained from
PromoCell (Heidelberg, Germany) and were grown in full
Endothelial Growth Medium (Endothelial Cell Growth
Medium plus SupplementMix, both from PromoCell).
Human peripheral blood mononuclear cells (PBMCs) were
prepared from heparinized blood from healthy donors by
density gradient centrifugation (Biocoll density = 1.077 g/
ml, Biochrom, Berlin, Germany) as described.62 Monocytes
and T cells were isolated from PBMCs by positive selection
with anti-CD14 or anti-CD3 magnetic beads (Miltenyi
Biotec, Bergisch Gladbach, Germany), respectively, accord-
ing to the manufacturer’s protocol. Monocytes were differ-
entiated into DCs with 40 ng/ml IL-4 and 20 ng/ml GM-
CSF (both from R&D Systems, Heidelberg, Germany) in
X-Vivo 15 medium (Lonza) supplemented with 100 units/
ml penicillin, 0.1 mg/ml streptomycin, and 10% autologous
serum for a minimum of 5 days. IL-4 and GM-CSF were
refreshed after 3 days.
Human PMNs were isolated after density gradient cen-
trifugation of heparinized blood from the resulting ery-
throcyte-granulocyte pellet via hypotonic lysis of
erythrocytes (hypotonic buffer: 0.15 M NH4Cl, 0.01 M
NaHCO3, 0.001 M EDTA in H2O). After washing, freshly
isolated PMNs were employed for flow chamber
experiments.
The production of cell-free supernatants of x-ray irradiated
HCC1937, HCC1806, and MDA-MB-436 cells was described
previously.27 Briefly, 0.5-1x106 cells were seeded into 6-well
plates, and adherence was allowed overnight. Immediately
before x-ray irradiation, cell culture medium was changed to
RPMI-1640 or DMEM/F12 medium containing 2.5% FCS,
respectively. X-ray irradiation at the indicated doses was per-
formed with an RS225 x-ray cabinet (X-Strahl, Camberley,
UK) operated at 200 kV and 10 mA (Thoraeus filter, 1 Gy
in 63 s). A single dose of 2 Gy, daily doses of 2 Gy in the
fractionated setting, a single ablative dose of 20 Gy, or sham
irradiation at 0 Gy were used, respectively. Four days after
irradiation, culture supernatants were harvested, cleared by
centrifugation (10,000 g, 5 min), and stored at −80°C until
further use.
In the biochemical characterization experiments, superna-
tants of irradiated HCC1937 cells were treated by membrane
centrifugation using VivaSpin2 tubes with a molecular weight
cut-off of 10 kDa (Sartorius, Goettingen, Germany). Upon
centrifugation, both fractions (molecular weight smaller or
larger than 10 kDa) were re-adjusted to the initial volume
before experiments were performed. Alternatively, the super-
natants were digested by 20 µg/ml proteinase K (New England
Biolabs, Frankfurt, Germany) for 30 min at 37°C. Proteinase
K was subsequently heat-inactivated at 95°C for 50 min. As a
control, incubation was carried out with heat-inactivated pro-
teinase K.
HUVEC stimulation was performed with diluted cell-
free supernatants of irradiated HCC1937 cells (1:2 in full
Endothelial Growth Medium) for 4 h. For cytokine ana-
lyses, medium was afterwards replaced, and supernatants
were collected after 2 h in order to make sure that
HUVECs and not breast cancer cells are the sources of
the secreted cytokines. TNF (50 ng/ml, R&D Systems) in
full Endothelial Growth Medium served as positive con-
trol, and lipopolysaccharide from R. sphaeroides (RS-LPS
ultrapure, 10 µg/ml, InvivoGen) was used to block activa-
tion of TLR4.
Air pouch model
All animal experiments were performed in accordance with
the Federation of European Laboratory Animal Science
Associations (FELASA) guidelines and were approved by the
regional government of Upper Bavaria (Regierungspräsidium
Oberbayern). Mice were kept under standard conditions in
individually ventilated cages (IVCs) with a 12 h day/night
cycle throughout the experiments. Food and water were pro-
vided ad libitum. Upon air pouch generation, mice were
housed individually.
Air pouch generation, stimulation, and harvest
Air pouches were generated by s.c. injection of 5 ml sterile air
into the depilated backs of 9–10 weeks old female BALB/c
mice. After 3 days, pouch sizes were re-adjusted by injection
of 2–3 ml sterile air. Experiments were started 6 days after air
pouch generation (Figure 1(a)). 1 ml of air was withdrawn
from the pouch and replaced by 1 ml of cell culture super-
natant, control medium (RPMI-1640 medium supplemented
with 2.5% FCS), or TNF solution (50 ng/ml in RPMI-1640
medium supplemented with 2.5% FCS), respectively. 3 h, 6 h,
12 h, and 24 h after injection, mice were euthanized, and air
pouch lavages were collected by washing the pouches with
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3 × 2 ml saline (B. Braun, Melsungen, Germany). Afterwards,
air pouch skin samples were harvested by surgical excision
and fixed in isotonic 3.5% formaldehyde solution for 1 h.
Upon washing in PBS, the fixed skin samples were subjected
to H&E histochemistry staining or confocal immunofluores-
cence microscopy, respectively.
H&E histochemistry and confocal immunofluorescence
microscopy of air pouch skin samples
For H&E histochemistry, fixed skin samples were embedded
in paraffin. 3 µm sections were cut transversally to the muscle
fibers, dewaxed in xylene (VWR, Darmstadt, Germany) and
rehydrated in a decreasing series of ethanol. Rehydrated sec-
tions were stained with hematoxylin staining solution (Merck
Millipore, Darmstadt, Germany), and blued in water.
Subsequently, skin sections were stained with eosin staining
solution (Sigma-Aldrich, Taufkirchen, Germany), followed by
dehydration in an increasing ethanol series. Finally, stained
sections were embedded in Entellan (Merck Millipore), and
microscopy was performed on a Zeiss Lab A1 microscope
(Carl Zeiss, Jena, Germany) at 20x magnification.
For confocal immunofluorescence microscopy, fixed air
pouch skin samples were first permeabilized in 0.1% Triton
X-100 containing 2% BSA (Sigma Aldrich) at 4°C overnight.
Skin samples were then stained with anti-F4/80-Alexa
Fluor488 (Thermo Scientific), anti-PECAM-1-Alexa
Fluor647, and rat anti-Ly6G antibodies (both from
BioLegend, Koblenz, Germany) at 4°C for 72 h. Afterwards,
samples were washed three times in PBS and incubated with
the secondary anti-rat IgG-Alexa Fluor546 antibody (Thermo
Scientific) for 3 h at room temperature. The stained samples
were washed again, embedded in PermaFluor mounting med-
ium (Thermo Scientific), and subjected to confocal micro-
scopy on a Leica TCS SP5 Confocal microscope (Leica
Microsystems, Wetzlar, Germany) at 20x magnification.
Flow cytometry
All flow cytometry experiments were performed on an LSR II
cytometer (BD Biosciences, Heidelberg, Germany), and data
were analyzed by FACSDiva (BD Biosciences) or Flowjo 7.6.5
software (Tree Star, Ashland, OR, USA), respectively.
Air pouch-infiltrating leukocyte subsets
From air pouch lavages, cells were collected by centrifugation
(314 g, 5 min), resuspended in FACS staining buffer (BD
Biosciences), and stained with anti-CD45-APC-Cy7, anti-
Ly6C-PE-Cy7, anti-Ly6G-BUV395 (all from BD Biosciences),
anti-CD11b-FITC, anti-CD11c-PerCP-Cy5.5, anti-F4/80-
eFluor450, anti-H-2-Alexa Fluor700, anti-PDCA1-APC, and
anti-Siglec-H-PE (all from Thermo Scientific) antibodies or
the corresponding isotype controls for 30 min on ice in the
dark. Cells were washed twice in FACS staining buffer before
FACS analysis was performed. The FACS gating strategy for
leukocyte subset identification is depicted in Supplemental
Figure 2. Total cell numbers for each leukocyte subset were
calculated on the basis of all CD45+ cells counted in the air
pouch lavage.
DC surface markers
Monocyte-derived DCs were stained with anti-CD40-PE-Cy5,
anti-CD80-PE, anti-CD83-PE-Cy7, anti-CD86-Alexa Fluor700,
anti-HLA-DR-PerCP-Cy5.5 antibodies or the matching isotype
controls in FACS staining buffer (all from BD Biosciences) for
30 min on ice. After two washing steps with FACS staining
buffer, cells were subjected to flow cytometry. Relative surface
marker expression was calculated from the median fluorescence
intensities subtracted by the corresponding isotype controls and
normalized on the 0 Gy controls.
Phagocytosis assays
Phagocytosis assays were performed as reported previously.63
In brief, isolated primary human monocytes were stained with
the green membrane labeling dye PKH67 (Sigma-Aldrich)
and differentiated into DCs as described above. HCC1937
cells were stained with the orange membrane labeling dye
PKH26 (Sigma-Aldrich) and seeded into 24-well plates (0.3-
1x105 cells/well) prior to irradiation at the indicated doses.
Four days after irradiation, DCs were co-incubated with
HCC1937 cells in increasing target:effector ratios at 37°C for
2 h. Subsequently, cells were collected by trypsinization and
subjected to flow cytometry. The percentage of phagocytosis
was determined as the percentage of PKH67/26 double-posi-
tive DCs on the basis of all DCs deployed. In order to confirm
true engulfment, DCs were incubated with 20 µM of the actin
polymerization inhibitor cytochalasin D (Sigma-Aldrich) for
1 h prior to the phagocytosis assay.
Allogeneic mixed leukocyte reaction
Primary human monocytes were stimulated with super-
natants of irradiated HCC1937 cells or TNF (100 ng/ml)
and differentiated into DCs as described. After 7 days,
DCs were seeded into 96-well f-bottom plates (2x104 cells
per well) in 100 µl serum-free X-Vivo 15. On the same
day, T cells from an allogeneic blood donor were isolated
and labeled with 0.5 µM carboxyfluorescein succinimidyl
ester (CFSE, Thermo Scientific) with 1 × 106 T cells/ml in
0.1% BSA in PBS for 10 min at 37°C. Labeled T cells were
washed three times in serum-free X-Vivo 15 and added to
the DCs in X-Vivo 15 supplemented with 20% autologous
serum (ratio DCs:T cells of 1:5) yielding a final volume of
200 µl with 10% autologous serum. Co-incubation was
allowed for 5 days. Afterwards, cells were collected, and
T cells were stained with anti-CD3-PE-Cy7, anti-CD4-PE,
and anti-CD8-APC antibodies or the corresponding iso-
type controls (all from BD Biosciences) in 50 µl FACS
staining buffer for 30 min on ice. Stained T cells were
washed twice before flow cytometric analyses.
Proliferation of T cells was assessed as the percentage of
CD3+CD4+CFSElow or CD3+CD8+CFSElow T cells on the
basis of all CD3+CD4+ or CD3+CD8+ T cells, respectively,
and normalized on the 0 Gy samples.
Immunofluorescence microscopy
For immunofluorescence analyses, a Carl Zeiss AxioObserver
Z1 inverted microscope with an AxioCam Mr3 camera, a
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Zeiss Plan-Neofluar 63X/1.3 glycerol objective, an incubator
unit XLmulti S1 connected to the heating unit XL S with
TempModule S1 and CO2 Module S1, and the AxioVision
4.8 software package (all from Carl Zeiss) was used.
Morphology of breast cancer cells upon irradiation with
different regimens
HCC1937 cells were seeded onto sterile cover slips into 24-
well plates (4x104 cells per well) and incubated for adherence
overnight. On the next day, HCC1937 cells were irradiated at
the indicated doses and fixed on day 1 and 4 after irradiation
for 10 min with an isotonic solution of 3.7% formaldehyde
(Merck Millipore, Darmstadt, Germany) and 0.1% Triton
X-100 (Sigma-Aldrich). After washing in PBS, cells were per-
meabilized for 5 min in isotonic 0.5% Triton X-100 and
subsequently blocked for 1 h with 3% BSA (Sigma-Aldrich)
and 0.1% Triton X-100 in PBS. Cells were labeled with
Phalloidin-Alexa Fluor568 (Thermo Scientific) and anti-β-
tubulin-FITC antibody (Sigma-Aldrich) for 1 h in the dark.
Subsequently, labeled cells were washed in 0.1% Triton X-100
in PBS and stained with Hoechst-33342 (2 µg/ml; Sigma-
Aldrich) for 5 min. After 4 additional washing steps, slides
were mounted with Fluoromount (Sigma-Aldrich) and sub-
jected to microscopy. 25 z-stacks with 250 nm distance were
recorded and deconvolved using the AxioVision 4.8 software
(applied mode: Iterative).
Adhesion molecule surface expression on endothelial cells
HUVECs were stimulated 48 h after seeding onto sterile
coverslips with 400 µl of diluted supernatants of irradiated
HCC1937, HCC1806, MDA-MB-436 cells, or TNF, respec-
tively. Upon stimulation, HUVECs were washed with FACS
staining buffer before surface staining with anti-intercellular
adhesion molecule 1 (ICAM)-1-PE, anti-vascular cell adhe-
sion molecule 1 (VCAM-1)-PE, or anti-E-selectin-PE antibo-
dies (all from BD Biosciences) in FACS staining buffer was
allowed for 30 min in the dark. Hoechst-33342 (2 µg/ml) was
added for DNA staining. After two washing steps, slides were
mounted with Fluoromount and subjected to microscopy.
Live cell imaging
For live cell imaging of phagocytosis, PKH26-labeled
HCC1937 cells (0.3-1x105 cells/well) were seeded into 8-well
µ-slides (ibidi, Martinsried, Germany). Adherence was
allowed overnight, and cells were irradiated as described.
Phagocytosis by PKH67-labeled DCs was examined 4 d after
irradiation with a phagocyte:prey cell ratio of 1:1.
Phagocytosis was recorded at 37°C and 5% CO2 for 3.5 h at
20x magnification. Pictures were taken every 2 min.
Quantification of ICAM-1 and E-selectin surface
expression on endothelial cells
HUVECs were seeded into 96-well plates (9,000 cells/well) in
full Endothelial Growth Medium and incubated for 48 h.
Stimulation was performed with 190 µl of diluted superna-
tants of irradiated HCC1937 cells for 4 h. Full Endothelial
Growth Medium and TNF (50 ng/ml) served as controls.
Upon stimulation, cells were washed in FACS staining buffer
followed by incubation with anti-ICAM-PE, anti-E-selectin-
PE antibodies, or the matching isotype controls for 30 min on
ice in the dark. Subsequently, cells were washed twice, and
PE-fluorescence was measured on a Synergy Mx plate reader
(Ex. 480 nm, Em. 578 nm, BioTek, Berlin, Germany). Relative
surface expression of ICAM-1 and E-selectin was calculated
from the measured fluorescence intensities subtracted by the
corresponding isotype controls and normalized on the 0 Gy
samples.
Flow chamber assays
Flow chamber assays were performed as previously
described.64 Briefly, HUVECs were grown in ibidi flow cham-
bers (µ-Slide VI0.4)(µ-Slide VI4) for 48 h. Stimulation was
performed with 150 µl of diluted supernatants of irradiated
HCC1937 cells or TNF for 4 h. Then, flow chambers were
washed twice and perfused with primary human PMNs at a
concentration of 2.5x103 cells/ml with a flow rate of 0.11 ml/
min (shear force = 0.2 dyn/cm2). Adherent cells were defined
as cells which did not move for more than 1 cell diameter in
one minute. This also included crawling cells, which were
identified as cells moving less than 1 cell diameter/min.
Cytokine multiplex-ELISA
Concentrations of cytokines in supernatants of stimulated
HUVECs were measured with the Bio-Plex Pro Human
Chemokine Assay on a Bio-Plex 200 system according to the
manufacturer’s protocol (Bio-Rad Laboratories, Munich,
Germany). Stimulation of HUVECs was performed in 6-well
plates (2x105 cells per well) with 2 ml of diluted supernatants
of irradiated HCC1937 cells for 4 h. Afterwards, medium was
changed to full Endothelial Growth Medium, and cell culture
supernatants were collected after 2h.
HSP70, HMGB1, and S100A8/A9 ELISA
Levels of HSP70 and HMGB1 in supernatants of irradiated
HCC1937, HCC1806, and MDA-MB-436 cells were measured
with the HSP70-DuoSet-ELISA kit (R&D Systems) and the
HMGB1-ELISA kit (IBL International, Hamburg, Germany)
according to the manufacturers’ protocols. S100A8/9 protein
levels were quantified as described.65
Quantitative realtime PCR
qRT-PCR was performed as reported previously.27 From air
pouch skin samples, total RNA was extracted with TRIzol
Reagent (Thermo Scientific) according to the manufacturer’s
protocol. From in vitro HUVEC experiments total RNA was
isolated with the NucleoSpin RNA II-Kit (Macherey and Nagel,
Dueren, Germany). Afterwards, 1 µg of total RNA was reversely
transcribed with 200 U Revert Aid H Minus M-MuLV reverse
transcriptase in the presence of 5 µM random hexamers, 5 µM
Oligo(dT)18, 1 U/µl Ribolock RNase inhibitor (all from Thermo
Scientific), and 500µM dNTPs (Promega, Heidelberg, Germany)
in a final volume of 20 µl or 50 µl, respectively. For qRT-PCR, the
resulting cDNA (20–80 ng) was mixed with 300 nM forward and
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reverse primers (all synthesized by Sigma-Aldrich), and amplifi-
cation was performed in 1x Maxima SYBR Green qPCR Master
Mix (Thermo Scientific) in a final volume of 20 µl with a standard
cycling protocol (10 min 95°C, 45x (15 s 95°C, 30 s 60°C)) on an
LC480 qPCR cycler (Roche Applied Science, Penzberg,
Germany). The primer sequences for mouse and human target
genes are listed in Supplemental Tables 1 and 2. Relative quanti-
fication was performed using the standard curve method, the
results were normalized on a matrix of 3–5 reference genes as
indicated, and calibrated on the given controls.
Detection of TLR activation by HEK-BlueTMhTLR2 and
HEK-BlueTM hTLR4 reporter cell lines
HEK-BlueTM hTLR cells were seeded in HEK-BlueTM
Detection medium into 96-well plates (50,000 cells/well)
which were pre-filled with 20 µl culture supernatants of irra-
diated breast cancer cell lines. LPS (10 ng/ml) or fibroblast-
stimulating lipopeptide-1 (FSL-1, Pam2CGDPKHPKSF,
10 ng/ml, InvivoGen) served as positive controls for hTLR4
or hTLR2 activation, respectively. TLR stimulation was
allowed for 7 h at 37°C. Subsequently, activity of secreted
alkaline phosphatase (SEAP) was measured kinetically in a
Synergy MX plate reader (10 h at 37°C, absorption at 630nm,
measurement every 2 min at 37°C) and calculated from the
slope of the corresponding regression lines. Relative TLR
activation was expressed as x-fold values of samples treated
with 0 Gy culture supernatants.
Statistical analyses
Data are presented as independent data points from individual
experiments unless stated otherwise. For time course experiments,
means ± standard deviation (SD) or standard error of the mean
(SEM) of the indicated number of animals or independent experi-
ments are shown. Normal distribution was confirmed by
Kolmogorov-Smirnov analysis, and group comparisons were per-
formed by two-tailed, unpaired Student’s t-test or two-way
ANOVA, respectively. If normality was rejected, two-sided exact
Wilcoxon rank test was employed. Multiple testing correction was
performed using the post hoc Bonferroni-Holm algorithm.
Principal component analysis (PCA) was carried out in
OriginPro 9.1 as previously described.66
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